Gossamer Bio, Inc.
https://www.gossamerbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gossamer Bio, Inc.
Finance Watch: Turnstone Biologics Launches 14th Biopharma IPO Of 2023
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs
X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
Gossamer Calls It Quits On BTK Inhibitor Following Patient Deaths
The company will devote resources to its program to develop seralutinib in pulmonary arterial hypertension after announcing that it would discontinue GB5121 in CNS lymphoma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AA BioPharma Inc.
- Adhaere Pharmaceuticals, Inc.
- GB006, Inc.
- Pulmagen Therapeutics LLP
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice